NCT05663203 A Web-Based Dyadic Intervention for Colorectal Cancer
| NCT ID | NCT05663203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 56 participants |
| Start Date | 2023-05-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 56 participants in total. It began in 2023-05-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies how well a web-based dyadic intervention works to manage psychoneurological symptoms for patients with colorectal cancer and their caregivers. Patients with colorectal cancer receiving chemotherapy experience severe and distressing psychoneurological symptoms that include fatigue, depression, sleep disturbance, pain, and cognitive dysfunction. When these co-occurring symptoms are undertreated, they negatively affect functional status, survival rates, and quality of life of patients as well as decrease health outcomes of their family caregiver. A critical need exists to develop an effective and novel intervention that focuses on patients with colorectal cancer receiving chemotherapy and their caregivers. A web-based dyadic intervention holds great promise to reduce psychoneurological symptoms burden and improve quality of life for patients with colorectal cancer receiving chemotherapy and advance intervention development and implementation in cancer supportive care and health equity.
Eligibility Criteria
INCLUSION CRITERIA Patients: * Age \>= 18 years * Diagnosed with colorectal cancer * Life expectancy \> 12 months * Receiving active chemotherapy * Self-reported at least two psychoneurological symptoms (based on the symptom measures' cutoff scores) * Identified primary caregiver (i.e., family members or significant others identified by the patients as their primary source of emotional and physical support) * Access to the Internet * Fluent in English Caregivers: * Age \>= 18 years * Primary caregiver * Access to the Internet * Fluent in English EXCLUSION CRITERIA Patients: • Karnofsky Performance Scale \< 50 Caregivers: • Have severe diseases (e.g., cancer, heart disease)
Contact & Investigator
Yufen Lin, PhD, RN
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT05663203 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05663203 currently recruiting?
Yes, NCT05663203 is actively recruiting participants. Contact the research team at yufen.lin@emory.edu for enrollment information.
Where is the NCT05663203 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT05663203 clinical trial?
NCT05663203 is sponsored by Emory University. The principal investigator is Yufen Lin, PhD, RN at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 56 participants.